Clinical Handbook of Psychotropic Drugs by Kalyna Z. Bezchlibnyk-Butler
Fully updated and expanded, in full color with intuitive icons throughout, packed with new and expanded comparison charts, and with patient handouts as printable PDFs - the classic reference to psychotropic medications is now more "userfriendly" than ever! The Clinical Handbook of Psychotropic Drugs has become a standard reference and practical tool for psychiatrists, psychiatric nurses, pharmacists, psychologists, physicians, and all mental health professionals.The new and fully updated 19th edition retains all the practical features for which the Clinical Handbook is renowned: Independent, unbiased Packed with unique comparison charts (dosages, side effects, pharmacokinetics, interactions - ) that allow you to see at a glance which medication is the most suitable for each patient Instantly recognizable icons and full color throughout, allowing you to find at a glance all the information you seek The latest information on newly released drugs, adverse effects, approved indications (see below for details) Succinct, bulleted information on all classes of medication: classification, available products (including US and Canadian trade names), on- and off-label indications (US FDA and Canada); pharmacology, dosing, pharmacokinetics; adverse effects, precautions, contraindications, toxicity; lab tests, precautions in young, old, and pregnant patients, nursing implications; drug interactions; patient instructions - all you need to know for each class of drug! The latest information on Herbal and "Natural" Products, Unapproved Treatments, ECT, BLT, rTMS Patient handouts as printable PDFs New in this edition: Substantial updates on antipsychotic dosages (2nd generation); Pharmacogenomics information for dementia drugs; Recent drugs / preparations added, such as Forfivo (bupropion), Levate (amitriptyline), Impril (imipramine pamoate), Mazepine (carbamazepine), Stavzor (valproate), Gralise (gabapentin), Horizant (gabapentin enacarbil), Trokendi XR (topiramate); Revised classification of antidepressants: vilazodone (Viibryd) as Serotonin-1A Agonist/Serotonin Reuptake Inhibitor